



## EXECUTIVE TEAM

### **Alan L. Crane**

*President & Chief Executive Officer*

### **John E. Bishop**

*Vice President, Pharmaceutical Sciences & Manufacturing*

### **Steven B. Brugger**

*Senior Vice President, Strategic Business Operations*

### **Barbara Rosengren**

*Vice President, Strategic Product Development*

### **Richard P. Shea**

*Vice President, Chief Financial Officer*

### **Lisa Carron Shmerling**

*Vice President, Legal Affairs*

### **Ganesh Venkataraman, Ph.D.**

*Senior Vice President, Research (Momenta Co-Founder)*

### **Susan K. Whoriskey, Ph.D.**

*Vice President, Licensing & Business Development*

## CORPORATE OVERVIEW

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) is a biotechnology company specializing in the detailed characterization and engineering of complex sugars. Momenta is applying its technology to create technology-enabled generic versions of sugar-based and other complex drug products, as well as improved and novel drug candidates. Momenta's proprietary technology enables precise characterization of chemical structures found in complex sugars and a thorough understanding of the chemical composition of complex drugs. Additionally, Momenta's proprietary technology provides a more complete understanding of the roles that the chemical structures of sugars play in cellular function, disease biology, and drug action.

Momenta has applied this understanding to build a diversified pipeline of development candidates and a novel discovery platform. The Company's pipeline includes:

- technology-enabled generic versions of multiple complex drugs, including M-Enoxaparin, a generic version of Lovenox<sup>®</sup>, as well as other complex drugs such as glycoproteins;
- a rationally designed anticoagulant with potential for improved clinical properties targeted for acute coronary syndromes;
- a drug delivery program focused on the non-invasive delivery of therapeutic proteins by a sugar-mediated transport mechanism; and
- and a drug discovery program, focused initially on the discovery of novel sugar-based therapies for oncology.


Momenta was founded based on research completed at Massachusetts Institute of Technology (MIT).

## PATENTS

Momenta has over 100 patents and patent applications related to its technology and drug products, through both internal patent filings and exclusive licensing arrangements with MIT and the Ernest Orlando Lawrence Berkeley National Laboratory at U.C. Berkeley.

## CURRENT PROGRAMS / AREAS OF FOCUS

Momenta is applying its understanding of complex sugars to develop novel as well as improved or generic versions of drugs addressing unmet needs in areas including cardiovascular disease, oncology, and non-invasive drug delivery.



#### THE POWER OF VISION:

*Sugars are one of the least understood or appreciated biomolecules in the human body. Sugars are found in abundance throughout the body, but understanding their structure and role in biology remains a challenge.*

*Where others see a challenge, we see an opportunity.*

---

#### BOARD OF DIRECTORS

**Peter Barrett, Ph.D.** *Chairman, Momenta Pharmaceuticals, Inc., Former Chief Business Officer, Celera*

**John K. Clarke** *Managing General Partner, Cardinal Partners*

**Alan L. Crane** *Chief Executive Officer, Momenta Pharmaceuticals, Inc.*

**Marsha Fanucci** *Senior Vice President and CFO, Millennium Pharmaceuticals, Inc.*

**Paul Goldenheim, M.D.** *Former President, Transform Pharmaceuticals, Inc.*

**Peter Barton Hutt, LLB, LLM** *Former Chief Counsel, Food and Drug Administration*

**Robert Langer, Jr., Sc.D.** *Kenneth J. Germeshausen Professor of Chemical & Biomedical Engineering, MIT (Momenta Co-Founder)*

**Stephen Reeders, D.M., MRCP** *Chief Executive Officer, MVM International Life Science Partners*

**Ram Sasisekharan, Ph.D.** *Professor of Biological Engineering, MIT (Momenta Co-Founder)*

**Bennett M. Shapiro, M.D.** *Former Executive Vice President, Merck & Co., Inc.*

